Real-world GPP data show low uptake of targeted IL-36 inhibitors and persistent reliance on corticosteroids and non-GPP ...

Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...

Dr Ablon discusses important key points providers should keep in mind during their evaluations of patients seeking aesthetic ...

Risk for ischemic stroke, myocardial infarction were increased with prolonged use with doses >1 mg/day for more than one year ...

BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents with severe alopecia areata.

Holding meds does not enhance humoral immunogenicity and is associated with disease flares for patients with inflammatory arthritis ...

The novel oral helicase-primase inhibitor offers a non-intravenous option for immunocompromised adults with mucocutaneous HSV refractory to standard antivirals.

Statin treatment also associated with lower risks for treatment escalation, including surgery, topical ocular hypotensive prescription.

"Because evidence on GLP-1 exposure during breastfeeding remains limited, rising postpartum initiation warrants further study." HealthDay News — Postpartum initiation of glucagon-like peptide-1 ...

Adjuvant atezolizumab combined with mFOLFOX6 halved the risk of disease recurrence or death in patients with resected stage III mismatch repair–deficient colon cancer in the phase 3 ATOMIC trial.

Many approved prescriptions are never filled, with fill rates dropping sharply when out-of-pocket costs exceed $175.

Second study shows that individuals exposed to GLP-1 RAs have significantly higher prevalence rates of hair and scalp involvement.